Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Lundbeck Files Anti-CGRP Antibody Eptinezumab in Japan
Lundbeck has filed its investigational anti-CGRP antibody eptinezumab in Japan for the prevention of migraine attacks — a step that could lead to the Danish pharma’s first marketing authorization in the country. The submission, made on November 14, is based…
To read the full story
Related Article
BUSINESS
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
- Japan Pharma Workforce Up Slightly; Generic Firms Drive Gains over 5 Years
April 10, 2026
- Zenyaku, Chugai to End Rituxan Co-Promotion in September
April 10, 2026
- Effexor’s GAD Nod Seen Boosting Diagnosis, Treatment in Japan: Expert
April 10, 2026
- MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…